The global cancer supportive care drugs market size was valued at USD 21.1 billion in 2018. It is projected to exhibit a CAGR of 1.0% during the forecast period.Large number of side-effects associated with cancer treatment, increasing uptake of biosimilars, rising expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are anticipated to drive the growth.
According to estimates from the International Agency for Research on Cancer (IARC), 12.7 million people are diagnosed with cancer and 7.6 million deaths are recorded every year. Lung and breast cancer are the most prominent cancer types with the highest demand for supportive care drugs.
China and India are among promising destinations for cancer supportive care market expansion. Factors such as growing uptake of biosimilar, beneficial healthcare reforms, and low-cost base are providing a fillip to the market in these two countries.
Several unmet needs remain in the cancer supportive care segment. Current treatment approaches provide only symptomatic relief. Effective analgesic drugs with lower risk of tolerance and abuse remain a key area of unmet need in the cancer supportive drugs market.
The major drug classes involved in cancer supportive care include G-CSFs for treatment of neutropenia (CIN), ESAs for Anemia (CIA), antiemetics for nausea and vomiting (CINV), bisphosphonates for cancer induced bone diseases, and opioids and NSAIDs for treatment of cancer pain. Among these therapeutic classes, granulocyte stimulating factors (G-CSFs) such as Amgen’s Neupogen and Neulasta accounted for the largest share in 2018 followed by opioids. The report highlights brands prescribed in cancer supportive care such as Amgen’s Neupogen, Neulasta, Epogen and Xgeva, Merck’s Emend, Roche’s NeoRecormon, Helsinn’s Aloxi, Heron’s Sustol, and Cinvanti among others.
The share for G-CSF drug class is expected to decline through the forecast period due to key patent losses and less use of myelosuppressive chemotherapy. Class of G-CSFs and ESAs have seen most number of biosimilar products, which has enabled increased access to affordable care for patients. Anti-emetics drug class is anticipated to post healthy growth during the same period, owing to new product launches. Targeted therapies currently dominate the space and are estimated to grow during the forecast period. Factors such as increasing use of immuno-oncology agents are poised to restrain the growth of the cancer supportive care drugs market over the coming years.
Currently more than 10 products are undergoing clinical trials for treatment of various side-effects of cancer therapy. Some of the drugs are poised to aim at new molecular targets for treating side-effects in the cancer supportive care segment. Several key players are projected to work towards addressing unmet needs, identifying new targets, and consequentially develop stronger drug pipelines.
As per the findings of the report, leading pipeline drugs such as Tanezumab and Rolontis are likely to be launched during the forecast period. Results from clinical trials of these drugs reported positive primary and secondary endpoint data. These drugs utilize improved drug delivery technologies to optimize efficacy and lower adverse side-effects.
North America led the market with more than 42.0% share in 2018. While the number of biosimilars launched in U.S. is low, biosimilar penetration is anticipated to increase owing to twice the average price of biologics.
Japan has witnessed significant uptake of biosimilars over the past few years. Rising incidence of cancer along with large number of side-effects associated with cancer treatment is one of the key factors anticipated to stimulate cancer supportive drugs market growth. Growing uptake of biosimilars, expenditure on healthcare, and availability of effective treatment methods, including target specific and tailored treatments are also benefiting the cancer supportive care market in Japan.
Some of the players operating in this market are Amgen, Johnson & Johnson, Merck, Roche, Helsinn Healthcare, Heron Pharma, and Tesaro. Approval of Sustol and Cinvanti are expected to create significant market opportunity for Heron Pharma during the forecast period. The company also has a Phase III product candidate indicated for cancer pain.
Patent expirations and rising biosimilar competition have impacted several companies, most notably Amgen and Roche. Sandoz, Hospira, Teva Pharmaceuticals, 3SBio, and BioSidus are some of the major players.
Attribute |
Details |
Base year for estimation |
2018 |
Actual estimates/Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Market representation |
Revenue in USD Million and CAGR from 2019 to 2026 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, France, Italy, Spain China, India, Japan, Thailand, South Korea, Mexico, Brazil, Argentina, Colombia, Saudi Arabia South Africa, UAE |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analysts working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global cancer supportive care drugs market report on the basis of therapeutic class and region:
Therapeutic Class Outlook (Revenue, USD Million, 2015 - 2026)
G-CSFs (Granulocyte-colony Stimulating Factors)
ESAs (Erythropoiesis Stimulating Agents)
Anti-emetics
Bisphosphonates
Opioids
NSAIDs
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Asia Pacific
India
China
Japan
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.